Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Cancer Chemotherapy and Pharmacology
|
April 6, 2022
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
Reeder M Robinson, Ashton P Basar, Leticia Reyes, et al.
European Journal of Haematology
|
May 1, 2012
Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma
Giampaolo Talamo, Kevin L Rakszawski, Witold B Rybka, et al.
Cancer Biology & Therapy
|
July 16, 2011
Spectral imaging-based methods for quantifying autophagy and apoptosis
Nathan G Dolloff, Xiahong Ma, David T Dicker, et al.
Science Translational Medicine
|
June 10, 2011
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation
Nathan G Dolloff, Patrick A Mayes, Lori S Hart, et al.
Leukemia Research
|
November 29, 2019
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo
Marquicia R Pierce, Reeder M Robinson, Tannya R Ibarra-Rivera, et al.
The American Journal of Pathology
|
October 7, 2011
High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors
Niklas K Finnberg, Lori S Hart, Nathan G Dolloff, et al.
Biomolecules
|
January 25, 2025
Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma
Nadia St Thomas, Benjamin N Christopher, Leticia Reyes, et al.
Cell Cycle (Georgetown, Tex.)
|
July 2, 2011
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab
Lori S Hart, Nathan G Dolloff, David T Dicker, et al.
Molecular Cancer Therapeutics
|
September 12, 2012
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9
Nathan G Dolloff, Joshua E Allen, David T Dicker, et al.
European Journal of Medicinal Chemistry
|
December 3, 2019
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor
Reeder M Robinson, Leticia Reyes, Ravyn M Duncan, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Cancer Chemotherapy and Pharmacology
|
April 6, 2022
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
Reeder M Robinson, Ashton P Basar, Leticia Reyes, et al.
European Journal of Haematology
|
May 1, 2012
Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma
Giampaolo Talamo, Kevin L Rakszawski, Witold B Rybka, et al.
Cancer Biology & Therapy
|
July 16, 2011
Spectral imaging-based methods for quantifying autophagy and apoptosis
Nathan G Dolloff, Xiahong Ma, David T Dicker, et al.
Science Translational Medicine
|
June 10, 2011
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation
Nathan G Dolloff, Patrick A Mayes, Lori S Hart, et al.
Leukemia Research
|
November 29, 2019
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo
Marquicia R Pierce, Reeder M Robinson, Tannya R Ibarra-Rivera, et al.
The American Journal of Pathology
|
October 7, 2011
High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors
Niklas K Finnberg, Lori S Hart, Nathan G Dolloff, et al.
Biomolecules
|
January 25, 2025
Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma
Nadia St Thomas, Benjamin N Christopher, Leticia Reyes, et al.
Cell Cycle (Georgetown, Tex.)
|
July 2, 2011
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab
Lori S Hart, Nathan G Dolloff, David T Dicker, et al.
Molecular Cancer Therapeutics
|
September 12, 2012
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9
Nathan G Dolloff, Joshua E Allen, David T Dicker, et al.
European Journal of Medicinal Chemistry
|
December 3, 2019
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor
Reeder M Robinson, Leticia Reyes, Ravyn M Duncan, et al.
Page
of 4